Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite itslimitations. Avacta has made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. Meanwhile, recognition that Affimers can hit specific targets in areas where antibodies have failed,
24 May 2017
Affimers 2 – Antibodies 0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Affimers 2 – Antibodies 0
Avacta Group PLC (AVCT:LON) | 44.5 -0.4 (-1.8%) | Mkt Cap: 159.8m
- Published:
24 May 2017 -
Author:
Martin Hall -
Pages:
4
Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite itslimitations. Avacta has made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. Meanwhile, recognition that Affimers can hit specific targets in areas where antibodies have failed,